This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Pluristem CEO Zami Aberman To Present At Phacilitate Cell & Gene Therapy Forum 2014

HAIFA, Israel, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell product candidates, today announced the Company's Chairman and CEO, Zami Aberman, will make two presentations and speak in panel discussions at the 10th Annual Phacilitate Cell & Gene Therapy Forum. The conference will take place on January 27 th through 29 th, 2014 in Washington D.C.

"We look forward to contributing to this year's Phacilitate Cell & Gene Therapy Forum by presenting our successful strategies in cell therapy development, manufacturing and clinical trials. This gathering, which includes the leaders in cell therapy science, investors, and regulators, is important to advancing the entire cell therapy industry to deliver much needed healthcare solutions," Mr. Aberman stated.

Mr. Aberman will be a panel member on the following sessions:

  • Date: Jan 28 th, 2014, 10:15AM ET

Panel Discussion Topic: How are phase I/II C&GT companies "blocking and tackling" to prepare for commercialization? What are the key questions to ask your development and commercial teams before you reach phase III?

  • Date: Jan 28 th, 2014, 05:20PM ET

Panel Discussion Topic: What are the key issues for consideration to assess the viability of such a business model?

Mr. Aberman will be the presenter for the following sessions: 

  • Date: Jan 29 th, 2014, 10:55AM ET

Topic: 3D culturing of MSC opens new possibilities for screening, toxicology and diagnostics

  • Date: Jan 29 th, 2014, 12:45PM ET

Focus Session 3 Case Study: The challenges in the design and implementation of a multi-national, FDA/EMA approved PAD clinical study

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs